FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

													-							
1. Name ar		2. Issuer Name and Ticker or Trading Symbol SANGAMO BIOSCIENCES INC [SGMO]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)									
RINGC	==	11 10			000		OLO II (C		, ,	X	Directo	or		10% O	wner					
-					- L										Officer	(give title		Other (s	specify	
(Last)	(F	irst)	3. [3. Date of Earliest Transaction (Month/Day/Year)									below)		below)		,			
	,	, IOSCIENCES II	` '			01/05/2015														
-,																				
POINT RICHMOND TECH CNTR, 501 CANAL																				
BLVD					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
					_								Li	ne)						
(Street)														X	Form f	iled by One	Repo	orting Perso	n	
	OND C	Λ	94804												Form filed by More than One Reporting					
RICHMOND CA 94804														Persor			·	ı		
					-															
(City)	(S	itate)	(Zip)																	
		Tab	le I - 1	Non-Deri	vative	e Sec	uriti	ies A	cquire	ed, D	isposed o	of, or B	eneficia	illy (Owned	t				
1. Title of Security (Instr. 3) 2. Transaction						2A. Deemed					4 Securities	Acquired (A) or			5. Amou	ınt of	6. Ownership		7. Nature	
Date						Execution Date,			3. Transa		Disposed Of (D) (Instr. 3, 4 and) Securit		ies For		m: Direct	of Indirect	
(Month/Day/Yea					//Year)	ar) if any (Month/Day/Year)		Code (Instr. 8)					Beneficially Owned Followin		(D) or Indirect (I) (Instr. 4)		Beneficial Ownership			
					// I Cai j			"					Reporte			(") (""		(Instr. 4)		
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3					
									\vdash			(0)			(IIISII. 3	J and 4)				
Common Stock 01/05/2019						5			M		2,200	A	\$6.41		3,	3,000		D		
					04=	_				2 200		* • • • • • • • • • • • • • • • • • • •	4(1)		000		_			
Common Stock 01/05/201					015	.5		S		2,200	200 D \$15.1		4(1)	4 ⁽¹⁾ 800			D			
		7	ahla i	II - Derivs	ntivo	Sacu	ritio	c // cr	uuirad	Die	sposed of	or Ro	neficial	<u>ν</u> Ο	wned					
		•	abic								, converti				wiieu					
				(e.g.,	puis,	Calls	, wa	IIIaiii	s, opt	10115	, convent	nie sec	unites							
1. Title of	2.	4.	5. Number		6. Date Exercisable and 7. Title and						3. Price of 9. Numbe				11. Nature					
Derivative Security	Conversion or Exercise	Date (Month/Day/Year)	Execu	tion Date,	Transa Code (Expiration Date Amount of (Month/Day/Year) Securities					Derivative Security (Instr. 5)		derivative Securities		Ownership Form:	of Indirect Beneficial	
(Instr. 3)	Price of	(World // Day / Tear)		n/Day/Year)	8)	Securities Acquired (A) or Disposed of (D)		urities	(Monthibay/rear)			Underlying				Beneficial		Direct (D)	Ownership	
	Derivative		l									Derivative Securi (Instr. 3 and 4)		у		Owned Following		or Indirect		
	Security		l									(IIISII. 3 aliu 4)				Reported		(I) (Instr. 4)	'	
			l													Transactio	n(s)			
						(Instr. 3, 4 and 5)										(Instr. 4)				
							1	-, 			1		Τ.	-						
			l										Amoun	1						
			l						l		L I		Number	١.						
					Code	l _v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	of Shares							
		-	_			<u> </u>	,					<u> </u>	+	+			-		+	
Stock Option												Commor								
(Right to	\$6.41	01/05/2015			M			2,200	(2	(.)	05/31/2021	Stock	2,200		\$0	7,800		D		
D	1	1	1		1			1	1		1	I	1	1		I				

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$14.71 to \$15.57, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- 2. All shares underlying this option are vested and immediately exercisable

Remarks:

/s/ Florence Tam, Attorney-in-Fact 01/06/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.